Form 4: BridgeBio Pharma Director Andrea Ellis Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Andrea Ellis exercised stock options and sold shares of BridgeBio Pharma, Inc. under a pre-arranged 10b5-1 trading plan.

Summary

• On April 1, 2025, Andrea Ellis, a director of BridgeBio Pharma, Inc. (BBIO), exercised stock options to acquire 30,000 shares of common stock at a price of $8.45 per share.
• Simultaneously, Ellis sold 30,000 shares of common stock at a price of $34.05 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 sales plan adopted on December 30, 2024.
• Following these transactions, Ellis directly owns 12,000 shares of common stock and 74,921 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There's no indication of positive or negative sentiment towards the company's prospects.

Future Outlook

NA

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like directors and officers, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 plan suggests the insider's trading activity is pre-planned and not based on any specific non-public information.

Comparison to Industry Standards

• Comparing the exercise price of $8.45 and sale price of $34.05 to other pharmaceutical companies' stock option plans, the exercise price is relatively low, indicating the options were granted some time ago or at a lower valuation.
• The use of a 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of insider trading, aligning with industry best practices for compliance and transparency.
• Similar filings from directors at comparable companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals are routinely scrutinized for similar insights into insider sentiment and trading strategies.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, BridgeBio Pharma, BBIO, Andrea Ellis, Stock Options, Share Sale, 10b5-1 Plan, Director, Insider Trading